QCM
CTKB icon

Quantinno Capital Management’s Cytek Biosciences CTKB Stock Holding History

Quantinno Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Buy
51,212
+21,564
+73% +$102K ﹤0.01% 3169
2025
Q4 		$150K Buy
+29,648
New +$138K ﹤0.01% 3097
2025
Q2 		– Sell
-21,190
Closed -$85K – 2584
2025
Q1 		$85K Buy
21,190
+6,970
+49% +$36.1K ﹤0.01% 2055
2024
Q4 		$92.3K Buy
+14,220
New +$84.7K ﹤0.01% 1622

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quantinno Capital Management's CTKB Position: Q1 2026 in Review

Quantinno Capital Management increased its Cytek Biosciences (CTKB) stake by 73% in Q1 2026, buying an estimated $102K and bringing the position to 51,212 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #3169.

Quantinno Capital Management first reported a position in CTKB in Q4 2024 and has held it in 4 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Quantinno Capital Management held 51,212 shares of Cytek Biosciences worth $224K as of Q1 2026.
  • Quantinno Capital Management bought 21,564 Cytek Biosciences shares in Q1 2026, an estimated $102K.
  • Cytek Biosciences made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #3169 holding.
  • Quantinno Capital Management first reported a position in Cytek Biosciences in Q4 2024 and has held it in 4 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.